Sugi Predict

Sugi Predict / Targets / AIP

AIP

AH receptor-interacting protein · O00170 · AIP on Sugi Atlas →

2,188 patent compounds predicted against AIP, 1,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Molibresib Molibresib (SCHEMBL1872390) 1.00 1/20
Molibresib Molibresib (SCHEMBL12671490) 1.00 1/20
Molibresib Molibresib (SCHEMBL12966358) 1.00 1/20
SCHEMBL9998851 SCHEMBL9998851 0.91 1/20
SCHEMBL14756282 SCHEMBL14756282 0.88 1/20
SCHEMBL12966165 SCHEMBL12966165 0.87 1/20
SCHEMBL14756215 SCHEMBL14756215 0.87 1/20
SCHEMBL14756339 SCHEMBL14756339 0.87 1/20
SCHEMBL9998825 SCHEMBL9998825 0.86 1/20
SCHEMBL1874116 SCHEMBL1874116 0.85 1/20
SCHEMBL12671221 SCHEMBL12671221 0.85 1/20
SCHEMBL14756021 SCHEMBL14756021 0.85 1/20
SCHEMBL14756240 SCHEMBL14756240 0.85 1/20
SCHEMBL14756287 SCHEMBL14756287 0.85 1/20
SCHEMBL14756335 SCHEMBL14756335 0.85 1/20
SCHEMBL14756409 SCHEMBL14756409 0.85 1/20
SCHEMBL14756206 SCHEMBL14756206 0.84 1/20
SCHEMBL14756217 SCHEMBL14756217 0.84 1/20
SCHEMBL14756343 SCHEMBL14756343 0.84 1/20
SCHEMBL14756138 SCHEMBL14756138 0.83 1/20

Clinical trials — most relevant to AIP by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer PHASE2COMPLETED
Fulvestrant in Hormone Refractory Prostate Cancer PHASE2COMPLETED
Fibrates in Pediatric Cholestasis PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia nanUNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA nanRECRUITING
Genetic Analysis for Predicting of Relapse During Steroid Treatment for Autoimmune Pancreatitis (AIP) nanCOMPLETED
Identification of Acute Intermittent Porphyria Modifying Genes nanRECRUITING
Observational Study of Acute Intermittent Porphyria Patients nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Autoimmune Pancreatitis, Pancreatic and Extrapancreatic cAnceR (AiPPEAR) nanUNKNOWN
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features nanUNKNOWN
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer nanUNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients nanUNKNOWN
Biomarkers in Idiopathic Juvenile Arthritis nanUNKNOWN
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card nanCOMPLETED
Biological Signatures Resulting From Occupational Exposure to Complex Mixtures of PAHs nanUNKNOWN
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart nanUNKNOWN
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis nanCOMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
The Role of Autoantibodies Against G-protein Coupled Receptors in Obesity nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a AIP binder may also engage these)

ProteinNameSimilarity
Q5FWY5 — 1.000 Q5FWY5 →
Q7YRC1 — 1.000 Q7YRC1 →
O97628 — 0.999 O97628 →
O08915 — 0.998 O08915 →
Q9JLG9 — 0.997 Q9JLG9 →
Q95MN9 — 0.997 Q95MN9 →
Q95MN8 — 0.997 Q95MN8 →
Q95MP0 — 0.995 Q95MP0 →
Q64378 — 0.995 Q64378 →
Q95MN7 — 0.994 Q95MN7 →
Q95L05 — 0.992 Q95L05 →
Q9VN19 — 0.991 Q9VN19 →
Q5RF88 — 0.991 Q5RF88 →
AIPL1 Aryl-hydrocarbon-interacting protein-like 1 0.991 landscape →
Q924K1 — 0.991 Q924K1 →
Q32PZ3 — 0.991 Q32PZ3 →
Q9VDE4 — 0.991 Q9VDE4 →
KDM5D Lysine-specific demethylase 5D 0.990 landscape →
B4LX81 — 0.990 B4LX81 →
Q95MP1 — 0.990 Q95MP1 →
Q75IP6 — 0.990 Q75IP6 →
Q6IQX0 — 0.990 Q6IQX0 →
Q4Q089 — 0.990 Q4Q089 →
Q8CGY6 — 0.990 Q8CGY6 →
P41230 — 0.989 P41230 →
P20192 — 0.989 P20192 →
Q5XUN4 — 0.989 Q5XUN4 →
H9IWW7 — 0.989 H9IWW7 →
DGKA Diacylglycerol kinase alpha 0.989 landscape →
Q8IUF1 — 0.989 Q8IUF1 →